Aisling Capital Management LP
Registered adviserRegulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
| Rosters | Regulatory AUM | Main clients |
|---|---|---|
| May 2023 to Jun 2023 | $332,674,494 | Pooled investment vehicles (98%) |
| Apr 2023 | $332,674,494 | Pooled investment vehicles (98%) |
| Apr 2022 to Mar 2023 | $494,257,919 | Pooled investment vehicles (100%) |
| Apr 2021 to Mar 2022 | $789,335,087 | Pooled investment vehicles (100%) |
| Apr 2020 to Mar 2021 | $431,630,100 | Pooled investment vehicles (100%) |
| Dec 2019 to Mar 2020 | $256,892,170 | Pooled investment vehicles (100%) |
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 99.6%; sector active share 90.6% against the combined 13F book's sector weights.
Over time 26 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
14 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $471,616,863 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increasedTrimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma, Inc. | −500,000 | 4,589,611 | $341,834,227 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| VTVT | vTv Therapeutics Inc. | 50,000 | $1,882,500 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| BBIO |
BridgeBio Pharma, Inc.
Healthcare
|
Reduced | 4,589,611 | $341,834,227 | 72.48% | |
| GLUE |
Monte Rosa Therapeutics, Inc.
Healthcare
|
Held | 1,555,664 | $37,647,068 | 7.98% | |
| SNDX |
Syndax Pharmaceuticals Inc
Healthcare
|
Held | 1,316,806 | $28,785,379 | 6.10% | |
| CMPS |
COMPASS Pathways plc
Healthcare
|
Held | 1,432,336 | $20,267,554 | 4.30% | |
| BCAX |
Bicara Therapeutics Inc.
Healthcare
|
Held | 568,919 | $16,891,205 | 3.58% | |
| BBOT |
BridgeBio Oncology Therapeutics, Inc.
Healthcare
|
Held | 1,018,018 | $7,757,297 | 1.64% | |
| SRRK |
Scholar Rock Holding Corp
Healthcare
|
Held | 77,031 | $4,236,705 | 0.90% | |
| URGN |
UroGen Pharma Ltd.
Healthcare
|
Held | 108,000 | $3,974,400 | 0.84% | |
| BMEA |
Biomea Fusion, Inc.
Healthcare
|
Held | 2,048,757 | $3,011,672 | 0.64% | |
| ACRS |
Aclaris Therapeutics, Inc.
Healthcare
|
Held | 434,455 | $2,298,266 | 0.49% | |
| EPRX |
Eupraxia Pharmaceuticals Inc.
Healthcare
|
Held | 325,000 | $2,148,250 | 0.46% | |
| VTVT |
vTv Therapeutics Inc.
Healthcare
|
NEW | 50,000 | $1,882,500 | 0.40% | |
| MRKR |
Marker Therapeutics, Inc.
Healthcare
|
Held | 325,370 | $478,293 | 0.10% | |
| OKUR |
OnKure Therapeutics, Inc.
Healthcare
|
Held | 88,607 | $404,047 | 0.09% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.